Remarkable strides have been made in targeting TET1 for therapeutic purposes, particularly in leukemia, colorectal cancer, triple-negative breast cancer, obesity, and schizophrenia, as summarized in Figure 4. This evidence concerns the gene TET1 and schizophrenia.